SEC Form 4 · accession 0001649245-26-000009
VERACYTE, INC. · VCYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillip G. Febbo
Officer — Chief Scientific & Med Officer
Period of report
Sep 2, 2026
Accepted (ET)
Sep 4, 2026 · 7:54 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001384101
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 2, 2026 | F | 3,639 | $44.88 | D | 146,158 | D | |
| Common StockF3 | Sep 4, 2026 | S | 10,405 | $42.8933 | D | 135,753 | D | |
| Common StockF4 | Sep 4, 2026 | S | 2,705 | $43.6618 | D | 133,048 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.
- F2The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
- F3Represents weighted average sales price. Sale prices for the transactions range from $42.47 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
- F4Represents weighted average sales price. Sale prices for the transactions range from $43.475 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.